The article titled “The Value of Health Care in the United States: Changes in Lifetime Spending and Health-Adjusted Life Expectancy, 1996 to 2016” investigates one of the most contested questions in contemporary health economics: whether the substantial growth in health-care expenditures in the United States has generated proportional improvements in population health outcomes. The study positions itself within the long-standing debate surrounding the apparent paradox of the U.S. health system, which combines the highest per-capita spending levels among high-income countries with comparatively modest gains in life expectancy and population health indicators. The authors argue that aggregate cross-national comparisons obscure critical within-system variation and therefore fail to provide an accurate assessment of health-care value.
Conceptually, the study departs from traditional cost-effectiveness analysis, which typically evaluates discrete clinical interventions such as pharmaceuticals, surgical procedures, or screening programs. Instead, it advances a system-level valuation framework that captures the cumulative contribution of the health sector across the full continuum of prevention, diagnosis, and treatment. This broader analytical lens allows the authors to estimate the value of health care across 132 disease and injury causes, thereby moving beyond intervention-specific productivity assessments toward a population health production function perspective.
To operationalize value, the authors construct a ratio between changes in lifetime health-care spending and changes in health outcomes. Health outcomes are measured using Health-Adjusted Life Expectancy (HALE), a composite metric that integrates both mortality and morbidity by adjusting survival years for time lived with disability. This methodological choice is significant because it addresses a core limitation of life expectancy as a standalone indicator, namely its inability to differentiate between additional years lived in full health and those lived with functional impairment.
Empirically, the study integrates data from two large-scale sources: the Global Burden of Disease (GBD) study, which provides cause-specific mortality and disability estimates, and the Disease Expenditure (DEX) accounts, which quantify health spending by condition. These datasets are harmonized by disease classification and age group to enable direct comparison between spending and health outcomes.
The central analytical technique employed is the cause-replacement simulation model. Within this framework, disease incidence is held constant at base-year levels, while outcomes per case and spending per case are replaced with those of the comparison year. By fixing the epidemiological burden and varying only treatment effectiveness and cost intensity, the model isolates the contribution of health-care technology and clinical practice improvements.
Findings indicate that between 1996 and 2016, improvements in health-care delivery increased both life expectancy and HALE, confirming that medical care contributed positively to population health. However, these gains were accompanied by substantial increases in lifetime health-care spending. When combined into a value ratio, the results suggest that the U.S. health system generated measurable health returns per unit of additional expenditure, though the magnitude of value varied significantly across disease categories.
To interpret this heterogeneity, the authors classify disease-specific results into four analytical quadrants defined by the direction of change in spending and HALE. Conditions characterized by simultaneous increases in spending and HALE represent high-value innovation zones, whereas those with rising expenditures but declining or stagnant HALE indicate potential inefficiencies. This quadrant framework offers a policy-relevant typology for prioritizing investment and reform.
A further contribution of the study lies in its life-course analytical perspective. The authors demonstrate that increases in health spending frequently occur at younger ages, whereas associated health gains materialize later in life. This temporal lag suggests that certain forms of medical expenditure function as long-term health investments, the returns of which are realized in older age cohorts. Consequently, value estimates restricted to elderly populations risk underestimating the full productivity of earlier health interventions.
The analysis also reveals substantial variation in value across disease groups. Advances in areas such as cardiovascular disease and HIV/AIDS generate considerable HALE gains relative to spending growth, reflecting technological innovation and therapeutic effectiveness. Conversely, some chronic and non-fatal conditions display rising expenditures with limited improvements in health outcomes, raising questions about allocative efficiency.
Despite its methodological breadth, the study acknowledges several limitations. First, the model does not fully incorporate changes in behavioral and environmental risk factors, which may influence both disease severity and treatment outcomes. Second, the period life-expectancy framework does not capture cohort-specific trajectories or long-term cumulative investment effects as precisely as longitudinal cohort models. Third, disability weight assumptions embedded in HALE calculations may underrepresent changes in morbidity over time.
In conclusion, the article advances the measurement of health-care value by integrating morbidity-adjusted survival with lifetime expenditure in a cause-specific, life-course framework. Its findings challenge aggregate critiques of U.S. health spending by demonstrating that medical care has generated meaningful health gains, albeit unevenly distributed across diseases and age groups. The study’s central implication is that policy debates should shift from the total volume of spending toward the distribution and productivity of spending across clinical domains.
Reference: Ackley, C., Dunn, A., Dwibedi, E., Fernando, L., Joffe, J., Mallatt, J., Dieleman, J. L., & Weaver, M. R. (2026). The value of health care in the United States: Changes in lifetime spending and health-adjusted life expectancy, 1996 to 2016. Value in Health. Advance online publication. https://doi.org/10.1016/j.jval.2026.01.008
Mini Dictionary (Key Concepts)
Health-Adjusted Life Expectancy (HALE): A population health metric that adjusts life expectancy by years lived with disability, reflecting both quantity and quality of life.
Lifetime Health Spending: The cumulative health-care expenditure incurred across an individual’s life course.
Cause-Replacement Method: A simulation technique that holds disease incidence constant while substituting outcome and spending parameters from another time period.
Value of Health Care
The ratio between health gains and health-care spending, often expressed as spending per HALE gained.
Period Life-Expectancy Framework: A demographic model that estimates expected survival using age-specific mortality rates from a given period.
Years Lived with Disability (YLDs): A morbidity measure quantifying non-fatal health loss weighted by severity.
Spending Effect: The change in lifetime expenditure attributable to advances in medical care.
Outcome Effect: The change in survival or HALE attributable to improvements in care quality or technology.
Value Quadrants: A four-cell classification mapping spending change against health outcome change.
Disease Expenditure Accounts: Condition-specific estimates of national health spending.